To view this email as a web page, click here

Today's Rundown

Featured Story

Roche to pay Blueprint $775M for pralsetinib rights, setting up showdown with Lilly

Roche is paying Blueprint Medicines $775 million upfront for rights to RET inhibitor pralsetinib. The deal sets Roche up to compete with Eli Lilly for patients with RET fusion-positive tumors of organs including the lung and thyroid.

read more

Top Stories

Sanofi, MD Anderson join forces to ramp up cancer R&D

Immuno-oncology drugs such as checkpoint inhibitors have transformed cancer treatment for some patients—the key word being “some.” Sanofi aims to understand why these drugs work for some patients and not others, and it’s teaming up with the MD Anderson Cancer Center to do it.

read more

FDA panel to chew over endpoint, safety strategies for Mallinckrodt’s terlipressin

Mallinckrodt unveiled phase 3 data in November showing its rare disease med terlipressin beat placebo at reversing a type of kidney failure. An FDA panel will convene on Wednesday to help the agency decide the drug’s fate—and their key question will be about the study’s surrogate endpoint.

read more

Sponsored: Kupffer Cells in Complex In Vitro Cultures: An Important Tool For Drug Discovery

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

read more

FDA spurns CytoDyn's HIV drug because of missing info

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV, because it’s missing some information, the company announced Monday. The refusal-to-file letter comes two months after the company revealed it had previously sent the wrong data sets to the agency.

read more

Junshi taps Revitope for next-gen anticancer bispecifics

Junshi Biosciences has struck a deal to source T-cell engaging antibodies from Revitope Oncology. The deal, which is worth up to $160 million per molecule in milestones, comes as Junshi tries to pull off a $684 million IPO to fund development of a broad pipeline of therapeutics.

read more

Mahanthappa graduates from Scholar Rock, hires Taris CEO Kingsley as new chief

After eight years at the helm, Scholar Rock’s founding CEO Nagesh Mahanthappa, Ph.D., is stepping down from the biotech to become its scientific adviser.

read more

A 'safety switch' for cell therapy based on nutrient deprivation

Startup Auxolytic is developing a “safety switch” for cell therapy that hinges on depriving engineered immune cells of the nutrient uridine, which they need to grow and proliferate. The technique inactivated transplanted T cells in mice, preventing a potentially dangerous rejection response.

read more

electroCore’s nerve stimulator authorized for asthma patients facing COVID-19

The bioelectric therapy developer electroCore received an agency green light for its vagus nerve stimulation device, aimed at reducing exacerbations in people potentially affected by the novel coronavirus and have difficulty breathing due to asthma.

read more

The top 15 pharma companies by 2026 sales

As the pharma industry enters a new decade, the world's largest drug companies are busy launching new meds, restructuring to focus on innovative offerings and eyeing new technologies. And despite challenges from the COVID-19 pandemic, analysts see growth ahead for many of them.

read more

Resources

Whitepaper: High-Loaded Dosage Forms: Novel Platform Expands Spray-Dried Dispersion Utility

A novel spray-dried dispersion platform has been developed to faciliate high drug load applications

Whitepaper: How to Harness the eISF to Accelerate Clinical Operations

Complimentary Download: How to connect to study sites remotely via the Electronic Investigator Site File (eISF) to streamline clinical operations. Insights from the largest eISF network in the world.

Whitepaper: Learn How to Navigate Pediatric Clinical Trials Under the New RACE Act

Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need.

On-Demand Webinar: Fuel gene therapy development and production with modern AAV workflows

On-demand video: fuel gene therapy development and production with modern AAV workflows.

With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before.

eBook: Cambrex eBook - Small molecules: 2020 vision

The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet.

White Paper: Patient Switching Behaviors Impact on Adherence and Engagement: A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes

How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.”

Whitepaper: You've Decided on a Multiparticulate Dosage Form. Now What?

Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project.

Webinar: Blockchain Innovations that Connect & Protect Merck's Supply Chain

Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain.

eBook: SUPERCHARGE INNOVATION: UNLEASH THE FULL FORCE OF LIFE SCIENCES

Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense.

Whitepaper: 4 Ways to Keep Pace with Big Pharma, Even On a Start-Up Budget

Learn four ways to squeeze more value from your limited R&D resources.

eBook: Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies

Download this eBook and Learn the Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies

Case Study: Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

Fact Sheet: Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events